advertisement

Accelerate your drug discovery pipeline with AI-powered molecular modelling

BioSim Pro · Trusted by 400+ research institutions globally · 30-day free trial

CRISPR base editing corrects sickle cell mutation in 97% of patient cells · Phase III mRNA cancer vaccine shows 44% reduction in recurrence · Gut microbiome linked to treatment-resistant depression — Nature study · Novo Nordisk acquires rare disease biotech for $3.2B · FDA grants breakthrough designation to novel Alzheimer's antibody ·
CRISPR base editing corrects sickle cell mutation in 97% of patient cells · Phase III mRNA cancer vaccine shows 44% reduction in recurrence · Gut microbiome linked to treatment-resistant depression — Nature study · Novo Nordisk acquires rare disease biotech for $3.2B · FDA grants breakthrough designation to novel Alzheimer's antibody ·

Gut bacteria reshape regulatory T-cells to achieve autoimmune remission without immunosuppression

17685

The human gut is home to trillions of microorganisms that play a crucial role in shaping our immune system. Recent advances in immunology and microbiome research are uncovering a powerful connection between gut bacteria and the regulation of autoimmune diseases. One of the most promising discoveries centers on how specific gut microbes can influence regulatory T cells (Tregs)—a specialized group of immune cells responsible for maintaining immune balance and preventing excessive inflammatory responses.

In autoimmune conditions, the immune system mistakenly attacks healthy tissues, often requiring long-term immunosuppressive treatments that can leave patients vulnerable to infections and other complications. However, emerging research suggests that certain beneficial gut bacteria can “reprogram” Tregs, enhancing their ability to suppress harmful immune activity naturally. This process offers a groundbreaking alternative: achieving autoimmune remission without broadly weakening the immune system.

These microbes produce metabolites such as short-chain fatty acids, which act as signaling molecules to promote Treg development and function. By restoring a healthy microbial balance—through diet, probiotics, or targeted microbial therapies—it may be possible to create an internal environment that supports immune tolerance rather than inflammation.

This approach marks a shift from conventional treatments toward precision medicine strategies that work with the body’s natural systems. Scientists are now exploring microbiome-based therapies tailored to individual patients, aiming to harness specific bacterial strains that can modulate immune responses effectively.

While still in the research phase, these findings open the door to safer, more sustainable treatments for autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. By leveraging the symbiotic relationship between gut bacteria and the immune system, the future of autoimmune care may move beyond suppression and toward true biological harmony.

Facebook
Twitter
LinkedIn

Get the free newsletter

Top news, trends & analysis from Biomed Today.

No spam · Unsubscribe anytime

Advertisement

MolDock Suite

MD simulation for academic & pharma teams.

Advertisement

Your advertisement here

Advertisement

Your advertisement here